Detalles de la búsqueda
1.
Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1.
N Engl J Med
; 373(8): 705-13, 2015 Aug 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-26196665
2.
A phase I randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and immunogenicity of a live-attenuated quadrivalent dengue vaccine in flavivirus-naïve and flavivirus-experienced healthy adults.
Hum Vaccin Immunother
; 18(5): 2046960, 2022 11 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-35290152
3.
Doravirine dose selection and 96-week safety and efficacy versus efavirenz in antiretroviral therapy-naive adults with HIV-1 infection in a Phase IIb trial.
Antivir Ther
; 24(6): 425-435, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31355775
4.
A Phase II, Randomized, Safety and Immunogenicity Trial of a Re-Derived, Live-Attenuated Dengue Virus Vaccine in Healthy Children and Adults Living in Puerto Rico.
Am J Trop Med Hyg
; 93(3): 441-453, 2015 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-26175027
5.
Forty-eight-week efficacy and safety and early CNS tolerability of doravirine (MK-1439), a novel NNRTI, with TDF/FTC in ART-naive HIV-positive patients.
J Int AIDS Soc
; 17(4 Suppl 3): 19532, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-25394041
6.
Sustained efficacy and safety of raltegravir after 5 years of combination antiretroviral therapy as initial treatment of HIV-1 infection: final results of a randomized, controlled, phase II study (Protocol 004).
J Acquir Immune Defic Syndr
; 61(1): 73-7, 2012 Sep 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-22743596
7.
Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients.
J Acquir Immune Defic Syndr
; 51(2): 163-74, 2009 Jun 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-19357529
8.
Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naive patients with HIV-1 infection.
J Acquir Immune Defic Syndr
; 52(3): 350-6, 2009 Nov 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-19648823
9.
Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study.
J Acquir Immune Defic Syndr
; 46(2): 125-33, 2007 Oct 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-17721395
10.
Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals.
J Acquir Immune Defic Syndr
; 43(5): 509-15, 2006 Dec 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-17133211
Resultados
1 -
10
de 10
1
Próxima >
>>